ОбзорГрафикНовостиTraderScreen

HSBC WAR. CALL 12/25 TDXP/  DE000HS9LHS5  /

gettex Zettex2
15.11.2024  17:37:07 Изменение-0.0200 Бид19:23:06 Предложение19:23:06 Базовый актив Цена исполнения Дата истечения Тип опциона
0.3800EUR -5.00% 0.3400
Величина цены спроса: 10,000		 0.3900
Величина цены предложения: 10,000		 TECDAX 4,200.00 EUR 19.12.2025 Call
GlobeNewswire 22.07 MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire 12.06.2018 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire 20.12.2016 Medigene announces outlicensing of AAVLP technology
GlobeNewswire 13.12.2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire 06.12.2016 Medigene AG to be included in TecDAX Index
GlobeNewswire 06.12.2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire 06.12.2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire 28.11.2016 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire 17.11.2016 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire 15.11.2016 MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 15.11.2016 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 15.11.2016 MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 15.11.2016 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 15.11.2016 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire 14.11.2016 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 08.11.2016 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire 07.11.2016 MorphoSys AG Reports Results for the First Nine Months of 2016
GlobeNewswire 03.11.2016 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire 02.11.2016 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire 28.10.2016 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
GlobeNewswire 20.10.2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire 17.10.2016 MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire 01.10.2016 MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire 01.10.2016 Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire 29.09.2016 MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis